FOOD AND DRUG ADMINISTRATION

Center for Drug Evaluation and Research ANTIVIRAL DRUGS ADVISORY COMMITTEE MEETING SUBCOMMITTEE FOR IMMUNOSUPPRESSANTS

TENTATIVE AGENDA

January 24, 2002 Gaithersburg Holiday Inn Two Montgomery Village Avenue Gaithersburg, MD 20879

NDA 21-083 Rapamune® (sirolimus) Oral Solution – Maintenance Regimen

14D11 21 003 Rupumune (shommus) Otal Solution Maintenance Regimen		
8:30 a.m.	Call to Order and Opening Remarks Introduction of Committee	Chair, AVAC, Subcommittee for Immunosuppressants
	Conflict of Interest Statement	Tara P. Turner, Pharm. D. Executive Secretary, AVAC
8:40 a.m.	FDA Introductory Remarks	Renata Albrecht, M.D. Acting Director Division of Special Pathogen and Immunologic Drug Products, FDA
8:45 a.m.		Sponsor Presentation
10:45 a.m.	Break	
11:00 a.m.	FDA Presentation	Rosemary Tiernan, M.D., M.P.H. Medical Officer Division of Special Pathogen and Immunologic Drug Products, FDA (Tentative Speaker)
12:00 p.m.	Lunch	(Tentative Speaker)
1:00 p.m.	Open Public Hearing	
2:00 p.m.	Charge to the Committee	Renata Albrecht, M.D. Acting Director Division of Special Pathogen

and Immunologic Drug

Products, FDA

2:10 p.m. Committee Discussion and Vote

5:00 p.m. Adjourn